US approval could mark the company's graduation to oncology.

Meanwhile, Tango tries again in PRMT5.

Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.

Halda, Accent and Vividion take more projects into phase 1.

Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.

But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.